Sustained Release Drug Delivery Systems are advancing rapidly with the integration of innovative technologies such as nanotechnology, advanced biomaterials, and computational modelling. These systems are designed to overcome the limitations of conventional dosage forms by providing controlled and prolonged drug release, thereby improving therapeutic efficacy and patient compliance. The incorporation of nanocarriers will improve drug solubility, stability, and targeting efficiency, enabling the development of hybrid delivery platforms. Additionally, the shift toward personalized medicine will allow SRDDS to be tailored based on individual patient characteristics, including genetic profile, metabolic rate, and disease condition, ensuring optimized dosing and reduced adverse effects. Furthermore, advancements in in vitro–in vivo correlation models will facilitate more accurate prediction of drug behaviour, support regulatory approval and improve formulation reliability. Overall, future SRDDS hold significant potential to transform drug delivery into a more efficient, safe, and patient-centric approach.
Sutar* et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: